Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
Ennio Giulio Favalli1,2*† 
Andrea Gobbini3† 
Mauro Bombaci3† 
Gabriella Maioli1,2 
Martina Biggioggero1 
Elisa Pesce3 
Andrea Favalli3 
Martina Martinovic3 Tanya Fabbris3 Edoardo Marchisio4 
Alessandra Bandera5,6,7 
Andrea Gori5,6,7 
Sergio Abrignani3† 
Renata Grifantini3† 
Roberto Caporali1,2†- 1Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan, Italy
- 2Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy
- 3Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- 4Dia.Pro, Diagnostic Bioprobes Srl, Milan, Italy
- 5Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- 6Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
- 7Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, Milan, Italy
by Favalli, E. G., Gobbini, A., Bombaci, M., Maioli, G., Biggioggero, M., Pesce, E., Favalli, A., Martinovic, M., Fabbris, T., Marchisio, E., Bandiera, A., Gori, A., Abrignani, S., Grifantini, R., and Caporali, R. (2022). Front. Med. 9:850858. doi: 10.3389/fmed.2022.850858
In the original article, an author name was incorrectly spelled as “Alessandra Bandiera.” The correct spelling is “Alessandra Bandera.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: seroprevalence, SARS-CoV-2, humoral response, rheumatic musculoskeletal diseases, disease-modifying anti-rheumatic drugs, risk of infection, COVID-19
Citation: Favalli EG, Gobbini A, Bombaci M, Maioli G, Biggioggero M, Pesce E, Favalli A, Martinovic M, Fabbris T, Marchisio E, Bandera A, Gori A, Abrignani S, Grifantini R and Caporali R (2022) Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. Front. Med. 9:923790. doi: 10.3389/fmed.2022.923790
Received: 19 April 2022; Accepted: 20 April 2022;
Published: 04 May 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Favalli, Gobbini, Bombaci, Maioli, Biggioggero, Pesce, Favalli, Martinovic, Fabbris, Marchisio, Bandera, Gori, Abrignani, Grifantini and Caporali. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ennio Giulio Favalli, enniofavalli@me.com
†These authors have contributed equally to this work